文献速递淋巴瘤

利妥昔单抗时代套细胞淋巴瘤年轻与老年患者的多中心实践模式与结局分析

Multi-center analysis of practice patterns and outcomes of younger and older patients with mantle cell lymphoma in the rituximab era.
PubMed 文献 · Am J Hematol · 2021-08-10

该研究纳入12家美国学术中心2000-2015年新诊断套细胞淋巴瘤患者1162例(<65岁697例,≥65岁465例),比较两年龄组的治疗模式、生存结局与预后因素。老年患者2年PFS和OS均劣于年轻患者,但维持利妥昔单抗及含大剂量阿糖胞苷诱导可减轻年龄对生存的负面影响。

要点

  • 老年(≥65岁)患者2年PFS 67%、OS 86%,均低于年轻患者的79%和92%。
  • 缺乏维持利妥昔单抗与两组PFS、OS不良均独立相关。
  • 一线大剂量阿糖胞苷暴露和/或维持利妥昔单抗可减轻年龄对生存的负面影响。

核心结论

  • 利妥昔单抗时代老年套细胞淋巴瘤患者生存仍劣于年轻患者。
  • 维持利妥昔单抗及潜在的大剂量阿糖胞苷诱导可减轻年龄对生存的负面影响。

研究设计与样本

  • 多中心回顾性分析,纳入12家美国学术中心2000-2015年新诊断套细胞淋巴瘤患者共1162例。
  • 年轻组(<65岁)697例,老年组(≥65岁)465例,比较实践模式、结局与预后因素。

主要发现

  • 年轻组2年PFS率79%、OS率92%;老年组2年PFS率67%、OS率86%。
  • 年轻组中母细胞样组织学、ECOG≥2及缺乏维持利妥昔单抗在单因素和多因素分析中均与较差OS相关。
  • 老年组中缺乏维持利妥昔单抗在单因素和多因素分析中均与较差PFS和OS显著相关(p<0.001)。
  • 2年PFS率<65岁为79%、≥65岁为67%,2年OS率分别为92%和86%(p<0.001)。

临床怎么用

  • 对老年套细胞淋巴瘤患者应考虑维持利妥昔单抗以改善生存。
  • 年轻患者中应关注母细胞样组织学、ECOG≥2等不良预后因素。
  • 一线可考虑含大剂量阿糖胞苷的诱导方案以减轻年龄的负面影响。

局限性

  • 为回顾性多中心分析,实践模式与治疗选择可能存在中心间异质性。
  • 原文未报告具体维持治疗方案、剂量及治疗持续时间等细节。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Clinical outcomes and predictors of survival in patients with newly diagnosed mantle cell lymphoma (MCL) treated in the rituximab era (2000-2015) at 12 US academic centers were assessed to identify determinants of survival across age groups. Objectives were to characterize and compare practice patterns, outcomes and prognostic factors for survival in younger patients (age < 65) and older patients (age ≥ 65 years). Among 1162 patients included, 697 were younger and 465 were older. In younger patients, 2-year progression free survival (PFS) and overall survival (OS) rates were 79% and 92% respectively; blastoid histology, ECOG ≥ 2, and lack of maintenance rituximab (MR) remained statistically relevant to poor OS on univariate analysis (UVA) and multivariate analysis (MVA). In older patients, 2-year PFS and OS rates were 67% and 86% respectively; lack of maintenance rituximab remained significantly associated with inferior PFS and OS on UVA and MVA (p < 0.001). Two-year PFS rates were 79%, and 67% and 2-year OS rates were 92% and 86% for ages < 65 and ≥ 65 respectively (p < 0.001). First-line high-dose cytarabine exposure and/or MR lessened the negative impact of age on survival. Taken collectively, survival outcomes for older patients remain inferior to those of younger patients in the rituximab era. However, maintenance rituximab and potentially high-dose cytarabine-based induction can mitigate the negative impact of age on survival.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Karmali R, Switchenko JM, Goyal S, et al. Multi-center analysis of practice patterns and outcomes of younger and older patients with mantle cell lymphoma in the rituximab era. Am J Hematol. 2021. PMID: 34324220. doi:10.1002/ajh.26306

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。